Crucial considerations for pipelines to validate circulating biomarkers for breast cancer

Radwa Ewaisha, Chelsea D. Gawryletz, Karen Anderson

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.

    Original languageEnglish (US)
    Pages (from-to)201-211
    Number of pages11
    JournalExpert Review of Proteomics
    Volume13
    Issue number2
    DOIs
    StatePublished - Feb 1 2016

    Fingerprint

    Biomarkers
    Pipelines
    Breast Neoplasms
    Exosomes
    Circulating Neoplastic Cells
    Recurrence
    Mammography
    Mortality
    Monitoring
    Autoantibodies
    Nucleic Acids
    Tumors
    Screening
    Breast
    Cells
    Imaging techniques
    Research
    Neoplasms
    Proteins

    Keywords

    • autoantibodies
    • Biomarker discovery
    • breast cancer
    • early detection
    • pipeline
    • PRoBE principles
    • validation

    ASJC Scopus subject areas

    • Molecular Biology
    • Biochemistry

    Cite this

    Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. / Ewaisha, Radwa; Gawryletz, Chelsea D.; Anderson, Karen.

    In: Expert Review of Proteomics, Vol. 13, No. 2, 01.02.2016, p. 201-211.

    Research output: Contribution to journalArticle

    @article{8fc2ea739db449f7b801612ca471fb78,
    title = "Crucial considerations for pipelines to validate circulating biomarkers for breast cancer",
    abstract = "Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.",
    keywords = "autoantibodies, Biomarker discovery, breast cancer, early detection, pipeline, PRoBE principles, validation",
    author = "Radwa Ewaisha and Gawryletz, {Chelsea D.} and Karen Anderson",
    year = "2016",
    month = "2",
    day = "1",
    doi = "10.1586/14789450.2016.1132170",
    language = "English (US)",
    volume = "13",
    pages = "201--211",
    journal = "Expert Review of Proteomics",
    issn = "1478-9450",
    publisher = "Expert Reviews Ltd.",
    number = "2",

    }

    TY - JOUR

    T1 - Crucial considerations for pipelines to validate circulating biomarkers for breast cancer

    AU - Ewaisha, Radwa

    AU - Gawryletz, Chelsea D.

    AU - Anderson, Karen

    PY - 2016/2/1

    Y1 - 2016/2/1

    N2 - Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.

    AB - Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.

    KW - autoantibodies

    KW - Biomarker discovery

    KW - breast cancer

    KW - early detection

    KW - pipeline

    KW - PRoBE principles

    KW - validation

    UR - http://www.scopus.com/inward/record.url?scp=84957437326&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84957437326&partnerID=8YFLogxK

    U2 - 10.1586/14789450.2016.1132170

    DO - 10.1586/14789450.2016.1132170

    M3 - Article

    VL - 13

    SP - 201

    EP - 211

    JO - Expert Review of Proteomics

    JF - Expert Review of Proteomics

    SN - 1478-9450

    IS - 2

    ER -